Key Capital Management
ORKA icon

Key Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Key Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-24
Closed -$2.25K – 867
2026
Q2 		$2.25K Buy
+24
New +$1.6K ﹤0.01% 562

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Key Capital Management's ORKA Position: Q3 2026 in Review

Key Capital Management sold out of Oruka Therapeutics (ORKA) in Q3 2026, closing a stake of 24 shares — an estimated $2.25K sold.

Key Capital Management first reported a position in ORKA in Q2 2026 and held it in 1 quarter. The position peaked at $2.25K in Q2 2026. 102 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Key Capital Management reported no remaining Oruka Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Key Capital Management sold 24 Oruka Therapeutics shares in Q3 2026, an estimated $2.25K.
  • Key Capital Management first reported a position in Oruka Therapeutics in Q2 2026 and held it in 1 quarter.
  • Key Capital Management's Oruka Therapeutics position peaked at $2.25K in Q2 2026.
  • 102 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Key Capital Management's 13F filing for Q3 2026, filed 3 Nov 2026.